Autopsy report · NCT03065959

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

“Lack of efficacy determined at interim analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 42 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Astellas Pharma Global Development, Inc.

Sponsor type

Industry

Conditions

Mobility Limitation

Interventions

reldesemtiv; Placebo

Participants

42

Sites

5

Countries

United States

Trials that died the same way

• Hydroxyurea in Primary Progressive Multiple Sclerosis
  “No efficacy (interim.analysis)” (87% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (85% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (82% match in meaning)
• ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients
  “Lack of effect in interim analysis” (81% match in meaning)
• A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
  “Interim assessment: Lack of efficacy” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.